Cargando…

The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose

Many countries have initiated a booster dose for COVID-19 vaccination. However, little is known about the association between adverse events to vaccination and individual psychological status and willingness to receive the booster dose. From December 1, 2021 to February 1, 2022, 474 participants ans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Liling, Liang, Haiyu, Liu, Li, Qiu, Wenji, Su, Liuhui, Yang, Haomin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Coronavirus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026905/ https://www.ncbi.nlm.nih.gov/pubmed/36798968 http://dx.doi.org/10.1080/21645515.2023.2176643

Ejemplares similares

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy
por: Della Polla, Giorgia, et al.
Publicado: (2023)

Willingness of college students to receive COVID-19 heterologous vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023)

Post-vaccination adverse reactions, decision regret, and willingness to pay for the booster dose of COVID-19 vaccine among healthcare workers: A mediation analysis
por: Luo, Chengwen, et al.
Publicado: (2022)

Willingness to pay for booster dose of COVID-19 vaccine among healthcare workers in Taizhou,China
por: Pan, Shuang-Jun, et al.
Publicado: (2022)

Determinants of the willingness of medical staff to vaccinate their children with a booster dose of the COVID-19 vaccine in Taizhou, China
por: Huang, Li-Li, et al.
Publicado: (2022)

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
por: Tung, Tao-Hsin, et al.
Publicado: (2022)

COVID-19 vaccine booster dose hesitancy among key groups: A cross-sectional study
por: Huang, Min, et al.
Publicado: (2023)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

Intention to receive a COVID-19 vaccine booster dose and associated factors in Malaysia
por: Wong, Li Ping, et al.
Publicado: (2022)

Neighborhood social cohesion is associated with the willingness toward the booster dose of COVID-19 vaccines among the Chinese older population
por: Qin, Chenyuan, et al.
Publicado: (2022)

Willingness toward COVID-19 vaccination, coadministration with other vaccines and receive a COVID-19 vaccine booster: a cross-sectional study on the guardians of children in China
por: Ma, Libing, et al.
Publicado: (2022)

Multi-dimensional psychosocial factors influencing the willingness to receive a COVID-19 vaccine booster: A survey among the public in Mainland China
por: Lin, Yulan, et al.
Publicado: (2022)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?
por: Sritipsukho, Paskorn, et al.
Publicado: (2023)

Booster vaccination is required to elicit and maintain COVID-19 vaccine-induced immunity in SIV-infected macaques
por: Li, Pingchao, et al.
Publicado: (2023)

Trajectory of COVID-19 vaccine hesitancy post-vaccination and public’s intention to take booster vaccines: A cross-sectional analysis
por: Salman, Muhammad, et al.
Publicado: (2023)

Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan
por: Terada-Hirashima, Junko, et al.
Publicado: (2023)

Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study
por: Zhang, Xiaqing, et al.
Publicado: (2023)

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
por: Das, Rituparna, et al.
Publicado: (2023)

Parents’ willingness to pay for their children’s COVID-19 vaccine in Taiwan, China: A cross-sectional study
por: Huang, Chun-Lian, et al.
Publicado: (2023)

Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland
por: Rzymski, Piotr, et al.
Publicado: (2021)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Increase over time of antibody levels 3 months after a booster dose as an indication of better protection against Omicron infection
por: Bingula, Rea, et al.
Publicado: (2023)

Coverage of primary and booster vaccination against COVID-19 by socioeconomic level: A nationwide cross-sectional registry study
por: Hansen, Bo T., et al.
Publicado: (2023)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

Comparable antigen-specific T cell responses in vaccinees with diverse humoral immune responses after the primary and booster BBIBP-CorV vaccination
por: Wei, Dong, et al.
Publicado: (2022)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
por: Kyaw, Moe H., et al.
Publicado: (2023)

Heterologous mRNA-based COVID-19 booster strategies: Comment
por: Yasri, Sora, et al.
Publicado: (2023)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
por: Gilbert, Danielle, et al.
Publicado: (2023)

Knowledge and willingness to receive a COVID-19 vaccine: a survey from Anhui Province, China
por: Li, Huoba, et al.
Publicado: (2022)

Author reply to “Heterologous mRNA-based COVID-19 booster strategies: Comment”
por: Das, Rituparna, et al.
Publicado: (2023)

Intention to receive COVID-19 vaccine and its health belief model (HBM)-based predictors: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection
por: Suah, Jing Lian, et al.
Publicado: (2022)

Adverse events after COVID-19 vaccination self-reported by healthcare workers are reliable
por: Cheng, Yandong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3hen91me1br5c4jocn4cqr6do